Breast & Ovarian Cancer Comprehensive Panel:
Sample Required: Buccal Swab (included in kit)
Number of Genes: 37
Genes included: ABRAXAS1, AKT1, ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, CTNNA1, DICER1, EPCAM, , FANCC, FANCM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PIK3CA, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SDHB, SDHD, SMARCA4, STK11, TP53, XRCC2
Description:
The Breast and Ovarian Cancer Comprehensive Panel sequences genes associated with an increased risk for hereditary breast cancer and hereditary ovarian cancer.
This panel includes genes associated with moderate to high risk of hereditary breast and ovarian cancer and has established clinical management guidelines for disease-causing variants. It also includes genes where there is some evidence of an association with breast and ovarian cancer.
If you inherited a disease associated variant in a gene related to breast or ovarian cancer, it increases (but does not guarantee) your chance of developing these cancers. the presence of mutations in some of these genes can change the optimal treatment of your cancer.
Who is this test for?
This panel is for patients with a breast or ovarian cancer diagnosis and may be appropriate for anyone with a personal or family history of breast/ovarian cancer. Testing is strongly recommended if your patient or a member of their family has been diagnosed with breast cancer before age 50, triple-negative breast cancer, male breast cancer, ovarian cancer or if there have been multiple cases of cancer in a single individual.
What are the potential benefits for breast cancer patients?
Confirming the presence of a pathogenic variant linked to breast cancer helps patients and their care team better monitor risk factors. Knowing the specific variant can lead to more targeted screening, treatment and follow up plans.
Genetic testing for hereditary cancer can:
Establish or confirm a diagnosis
Identify risk for other cancers and health conditions
Assist in modifying lifestyle changes
Result in more personalised treatment, which may include increased screening, pharmacological treatments, and prophylactic surgeries.